Method for determining neutralizing peptide in serum by liquid chromatography-tandem mass spectrometry
Through liquid chromatography tandem mass spectrometry determination method, combined with immunomagnetic bead enrichment and solid phase extraction technology, the mass-to-charge ratio of the neutralized peptides in serum was directly detected, solving the problem of inaccurate detection in the existing technology, and achieving high sensitivity, High specificity results.
Patent Information
- Application Number
- CN202411253613.6
- Authority / Receiving Office
- CN · China
- Patent Type
- Applications(China)
- Current Assignee / Owner
- Filing Date
- 2024-09-09
- Publication Date
- 2024-11-29
AI Technical Summary
Existing methods for detecting serum and peptidin levels have problems such as cross-reaction, inappropriate results due to icteric, hemolytic or cloudy samples, and lack verification of other detection principles.
The liquid chromatography tandem mass spectrometry method was used to remove impurities in serum samples through immunomagnetic bead enrichment and solid phase extraction. The mass-to-charge ratio of serum neutralized peptides was directly detected by LC-MS/MS system to improve detection specificity.
High sensitivity and specificity detection is achieved, avoiding interference from complex blood components and enhancing the accuracy of detection.
Smart Images

Figure CN119044384A_ABST
Abstract
Description
Technical Field
[0001] The invention relates to the technical field of biomedicine, in particular to a method for determining serum copeptin by liquid chromatography-tandem mass spectrometry. Background Art
[0002] With the continuous deepening of medical research, the detection of serum copeptin plays an increasingly important role in disease diagnosis, pathological research and biomarker discovery. The existing method for detecting serum copeptin levels is mainly immunological method. For example, method 1 (Morgenthaler, NG, et al., Assay for the measurement of copeptin, stable peptide derived from the precursor of vasopressin. Clin Chem, 2006. 52 (1): p. 112-9.) discloses a method for detecting serum copeptin levels, comprising: mixing 50 μL of serum or plasma sample, anti-copeptin monoclonal antibody (mouse) labeled with fluorescent dye Cyanine5.5 and anti-copeptin polyclonal antibody (sheep) labeled with Lummi4-Tb, and detecting and quantifying copeptin by detecting the delayed signal emitted by the immune complex based on TRACETM technology (time-resolved amplified cryptate emission technology). Method 2 (CN115184621A) discloses a copeptin detection reagent based on immune layer analysis and a preparation method thereof, comprising: S1, diluting carboxyl polystyrene nano fluorescent microspheres and colored polystyrene microspheres with a labeling buffer to a solid content of about 0.2%; S2, adding EDC solution and Sulfo-NHS-LC-Biontin biotin labeling test solvent to the above polystyrene nano fluorescent microspheres and colored polystyrene microsphere solutions, activating for 15 to 30 minutes, high-speed centrifugation for 20 minutes, removing the supernatant and adding an appropriate amount of anti-copeptin antibody solution, mixing and reacting for 1 to 1.5 hours; S3, using 0.1M, pH 7.0 phosphate buffer solution and pH 9.0, 0.1M sodium borohydride solution as coating solutions to examine the detection sensitivity and background level after coating, and selecting pH for the detection sensitivity and background level. 7.0 phosphate buffer solution as the coating solution of the FGF23 kit; S4, add the blocking solution to the polystyrene nano fluorescent microspheres, colored polystyrene microspheres solution and the anti-copeptin antibody coupling solution, react for 30 to 60 minutes, centrifuge at high speed for 20 minutes, remove the supernatant, and add the antibody preservation solution to obtain the anti-copeptin antibody polystyrene nano fluorescent microspheres and colored polystyrene microspheres labeling solution; S5, spray the obtained labeling solution onto the glass fiber or polyester fiber with a gold spray film instrument, the spray volume is 1 to 5 μL / cm, and after drying and cutting, the anti-copeptin antibody polystyrene nano fluorescent microspheres and colored polystyrene microspheres labeled with copeptin detection reagents are obtained. It can be seen that the above scheme has the following disadvantages and shortcomings:
[0003] 1) Immunoassays based on antigen-antibody binding may have cross-reactions, affecting specificity;
[0004] 2) Icteric, hemolytic, and lipemic samples, or samples that are turbid or contain fibrin may produce inaccurate results.
[0005] 3) Lack of validation based on other detection principles and methods. Summary of the invention
[0006] In order to overcome the deficiencies of the prior art, the object of the present invention is to provide a method for determining serum copeptin by liquid chromatography tandem mass spectrometry.
[0007] To achieve the above objectives, the present invention provides the following solutions:
[0008] The method for determining serum copeptin by liquid chromatography tandem mass spectrometry comprises:
[0009] Step 1: Add serum, internal standard solution, and magnetic beads coated with copeptin antibody to the centrifuge tube in sequence and mix thoroughly;
[0010] Step 2: Place the centrifuge tube on a magnetic stand to separate the magnetic beads and liquid, and discard the supernatant;
[0011] Step 3: Wash the magnetic beads with phosphate buffer and remove the buffer mixture;
[0012] Step 4: Add formic acid aqueous solution to the washed magnetic beads, mix thoroughly, and then add ammonia aqueous solution to form a sample;
[0013] Step 5: Add trypsin solution to the sample and place it on a shaker for full reaction to form a sample after enzyme digestion;
[0014] Step 6: performing solid phase extraction on the digested sample to form an extracted sample;
[0015] Step 7: Use LC-MS / MS system to analyze and detect the extracted sample to obtain a chromatogram of serum copeptin.
[0016] Preferably, the step 6, performing solid phase extraction on the digested sample to form an extracted sample, comprises:
[0017] Methanol was added to each well of the elution plate, and positive pressure elution was performed using nitrogen gas to activate each well, and pure water was added and positive pressure elution was performed using nitrogen gas again to balance each well;
[0018] Add ammonia solution to the sample after enzyme digestion, mix well and add to each plate well after activation and equilibrium, use nitrogen gas for positive pressure elution, and the formed target product is enriched in the filler of the plate well;
[0019] The target product is washed with an aqueous ammonia solution and methanol, respectively, to form a washed target product;
[0020] The washed target product was eluted with formic acid methanol solution, dried with nitrogen gas, and re-dissolved in acetonitrile aqueous solution to form an extracted sample.
[0021] Preferably, in step 7, an ACQUITY UPLC Peptide BEH C18 Column is used to perform liquid phase separation on the extracted sample, and mobile phase A is 0.03% ammonia solution, mobile phase B is acetonitrile, the liquid phase system performs gradient elution at a flow rate of 0.3 mL / min, and the column oven temperature is set to 40°C.
[0022] Preferably, in step 1, the copeptin internal standard is diluted with a 0.03% ammonia solution to form an internal standard solution.
[0023] Preferably, in step 4, the volume percentage concentration of the formic acid aqueous solution is 2%, and the volume percentage concentration of the ammonia aqueous solution is 10%.
[0024] According to the specific embodiments provided by the present invention, the present invention discloses the following technical effects:
[0025] The present invention provides a method for determining serum copeptin by liquid chromatography tandem mass spectrometry. Compared with the prior art, the present invention can effectively remove impurities in a serum sample by performing immunomagnetic bead enrichment and solid phase extraction on the serum, and then use an LC-MS / MS system to directly detect the mass-to-charge ratio of the serum sample, thereby increasing the detection specificity and avoiding interference from complex blood components. The method has the characteristics of high sensitivity and high specificity. BRIEF DESCRIPTION OF THE DRAWINGS
[0026] In order to more clearly illustrate the embodiments of the present invention or the technical solutions in the prior art, the drawings required for use in the embodiments will be briefly introduced below. Obviously, the drawings described below are some embodiments of the present invention. For ordinary technicians in this field, other drawings can be obtained based on these drawings without paying creative labor.
[0027] Figure 1 A flow chart of the method for determining serum copeptin by liquid chromatography tandem mass spectrometry provided by the present invention;
[0028] Figure 2 This is a typical spectrum obtained by detecting serum provided by the present invention. DETAILED DESCRIPTION
[0029] The following will be combined with the drawings in the embodiments of the present invention to clearly and completely describe the technical solutions in the embodiments of the present invention. Obviously, the described embodiments are only part of the embodiments of the present invention, not all of the embodiments. Based on the embodiments of the present invention, all other embodiments obtained by ordinary technicians in this field without creative work are within the scope of protection of the present invention.
[0030] Reference to "embodiments" herein means that a particular feature, structure, or characteristic described in conjunction with the embodiments may be included in at least one embodiment of the present application. The appearance of the phrase in various locations in the specification does not necessarily refer to the same embodiment, nor is it an independent or alternative embodiment that is mutually exclusive with other embodiments. It is explicitly and implicitly understood by those skilled in the art that the embodiments described herein may be combined with other embodiments.
[0031] The terms "first", "second", "third" and "fourth" in the specification and claims of the present application and the drawings are used to distinguish different objects rather than to describe a specific order. In addition, the terms "including" and "having" and any variations thereof are intended to cover non-exclusive inclusions. For example, a series of steps, processes, methods, etc. are not limited to the listed steps, but may optionally include steps that are not listed, or may optionally include other step elements inherent to these processes, methods, products or devices.
[0032] In order to make the above-mentioned objectives, features and advantages of the present invention more obvious and easy to understand, the present invention is further described in detail below with reference to the accompanying drawings and specific embodiments.
[0033] See also Figure 1 , a method for determining serum copeptin by liquid chromatography tandem mass spectrometry, comprising:
[0034] Step 1: Add serum, internal standard solution, and magnetic beads coated with copeptin antibody to the centrifuge tube in sequence and mix thoroughly;
[0035] Step 2: Place the centrifuge tube on a magnetic stand to separate the magnetic beads and liquid, and discard the supernatant;
[0036] Step 3: Wash the magnetic beads with phosphate buffer and remove the buffer mixture;
[0037] Step 4: adding formic acid aqueous solution to the washed magnetic beads, mixing thoroughly and then adding ammonia aqueous solution to form a sample; in step 4, the volume percentage concentration of the formic acid aqueous solution is 2%, and the volume percentage concentration of the ammonia aqueous solution is 10%.
[0038] Step 5: Add trypsin solution to the sample and place it on a shaker for full reaction to form a sample after enzyme digestion;
[0039] Step 6: performing solid phase extraction on the digested sample to form an extracted sample;
[0040] Further, step 6, performing solid phase extraction on the digested sample to form an extracted sample, comprising:
[0041] Methanol was added to each well of the elution plate, and positive pressure elution was performed using nitrogen gas to activate each well, and pure water was added and positive pressure elution was performed using nitrogen gas again to balance each well;
[0042] Add ammonia solution to the sample after enzyme digestion, mix well and add to each plate well of activation equilibrium, use nitrogen gas for positive pressure elution, and the formed target product is enriched in the filler of the plate well;
[0043] The target product is washed with an aqueous ammonia solution and methanol, respectively, to form a washed target product;
[0044] The washed target product was eluted with formic acid methanol solution, dried with nitrogen gas, and re-dissolved in acetonitrile aqueous solution to form an extracted sample.
[0045] Step 7: Use LC-MS / MS system to analyze and detect the extracted sample to obtain a chromatogram of serum copeptin.
[0046] In step 7, the present invention can use ACQUITY UPL C Peptide BEH C18 Column to perform liquid phase separation on the extracted sample, and the mobile phase A is 0.03% ammonia solution, the mobile phase B is acetonitrile, the liquid phase system performs gradient elution at a flow rate of 0.3 mL / min, and the column oven temperature is set to 40°C.
[0047] The present invention further illustrates the method for measuring serum copeptin of the present invention in conjunction with specific embodiments below:
[0048] First, the present invention needs to prepare the reagents in the process of measuring serum, and the specific process is as follows:
[0049] 1. Reagent preparation: Sample preparation solution, calibration solution, internal standard solution, instrument analysis solution are described as follows:
[0050] 1) Sample preparation solution: 0.03% ammonia solution (v:v), 5% serum solution (v:v), 2% formic acid solution (v:v), 10% ammonia solution (v:v)
[0051] 2) Stock standard solution: dilute with 0.03% ammonia solution.
[0052] Table 1
[0053]
[0054]
[0055] Calibration solution: dilute the stock standard solution 50 times with 5% serum solution
[0056] Table 2
[0057] Calibration solution Copeptin concentration (pg / mL) Level 1 5 Level 2 10 Level 3 20 Level 4 40 Level 5 100 Level 6 200 Level 7 400 Level 8 1000
[0058] 4) Internal standard solution: 5 ng / mL, diluted with 0.03% ammonia solution
[0059] 5) Trypsin reconstitution solution: 50 mM ammonium bicarbonate solution: weigh 0.79 g of ammonium bicarbonate powder and dissolve it in 200 mL of water.
[0060] 6) Reconstitution solution: 10% acetonitrile in water (v:v).
[0061] 7) Instrument analysis fluid:
[0062] Mobile phase A: 0.03% ammonia water;
[0063] Mobile phase B: acetonitrile.
[0064] 2. Sample pretreatment:
[0065] a) Immunomagnetic enrichment
[0066] Add 1000 μL serum or calibration solution or quality control, 20 μL internal standard, 100 μL magnetic beads coated with peptide antibody to a 1.5 mL EP tube and mix thoroughly. Vortex at 2000 rpm for 2 hours at room temperature. Place the EP tube on a magnetic stand, separate the magnetic beads and liquid, and discard the supernatant. Wash the magnetic beads with 300 μL phosphate buffer and discard the liquid. Add 30 μL 2% formic acid aqueous solution, vortex at 1700 rpm for 20 minutes at room temperature, and add 24 μL 10% ammonia solution to neutralize.
[0067] b) Trypsin digestion
[0068] Add 500 μL of 50 mM ammonium bicarbonate solution to 10 μL of trypsin stock solution (200 μg / mL). Prepare it before use. Add 50 μL of trypsin solution to each sample and place it on a shaker at 300 rpm, 37°C, for 4 hours.
[0069] c) Solid Phase Extraction
[0070] Add 200μL methanol to each well of the Oasis MAX 96-wellμElution Plate, and elute with nitrogen positive pressure; then add 200μL pure water, and elute with nitrogen positive pressure. Add 200μL 10% ammonia solution to the digested sample, mix well, add to the MAX plate wells, and elute with nitrogen positive pressure. Wash with 200μL 10% ammonia solution and methanol, elute with 100μL 5% formic acid methanol solution, and blow dry with nitrogen. Add 50μL 10% acetonitrile aqueous solution to re-dissolve. Take 40μL sample for LC-MS / MS analysis.
[0071] 3.LC-MS / MS conditions
[0072] The instrument used in this study was an LC-MS / MS system, which consisted of a Shimadzu HPLC system (Shimadzu, Japan) (liquid chromatograph) and a QTRAP 6500+ tandem quadrupole mass spectrometer (AB SCIEX, USA). An ACQUITY UPLC Peptide BEH C18 Column (2.1×100 mm; 2.7 μm) was used for liquid phase separation. Mobile phase A was 0.03% ammonia solution, and mobile phase B was acetonitrile. The liquid phase system performed gradient elution at a flow rate of 0.3 mL / min, and the column oven temperature was set to 40°C.
[0073] Table 1 Liquid phase gradient
[0074]
[0075]
[0076] Table 2 Quantitative ion pairs and parameters of MRM analysis of copeptin and its internal standard
[0077]
[0078] According to the properties of the compound, the present invention selects a suitable acquisition mode, specifically: positive ion, electrospray ionization, multiple reaction monitoring (MRM) mode. The quantitative ion pairs collected by MRM are shown in Table 2. Gas1, Gas2, curtain gas and collision gas are 60psi, 60psi, 30psi and medium respectively. The ion spray voltage is 5500v, and the optimal probe temperature is 400℃. The typical spectra detected by this method and the supporting reagents are as follows: Figure 2 shown.
[0079] 4. Performance verification and methodology comparison results
[0080] 1) Recovery rate: The spike recovery rate was evaluated by adding three concentrations of standard samples (addition concentrations were 20, 100 and 200 pg / mL) to the mixed serum. The verification was passed when the absolute value of the deviation was less than 20%. The results are shown in Table 3:
[0081] Table 3
[0082]
[0083] 2) Precision: The standard was added to the mixed serum to prepare three mixed serum samples with low concentration (about 30 pg / mL), medium concentration (about 100 pg / mL) and high concentration (about 200 pg / mL), and then the equal amount of serum was divided and stored at 80°C. Each mixed serum sample was measured 5 times a day for 5 consecutive days, and the precision results were calculated as shown in Table 4. According to the C64 "Quantitative Measurement of Proteins and Peptides by Mass Spectrometry" document of the Clinical and Laboratory Standards Institute (CLSI) of the United States, the total imprecision is ≤15% and the verification is passed.
[0084] Table 4
[0085]
[0086] 3) Matrix effect: The matrix effect was evaluated by adding serum from 6 individuals to the extracted samples. After extracting serum according to the sample preparation procedure, the synthetic enzymatic peptides and their internal standards were added to the samples, and two concentrations (1.25 ng / mL and 5 ng / mL) were set. The absolute response (peak area) and relative response (analyte / internal standard peak area ratio) of the standards were compared with the responses in serum obtained by pretreatment to evaluate whether the isotope-labeled internal standard can compensate for any matrix effects. The results are as follows: The absolute response values of the standards obtained from serum samples by immunocapture and solid phase extraction pretreatment were 137.4%-245.4% and 154.3%-163.8% of the standards in the solvent at 1.25 ng / mL and 5 ng / mL, respectively. After internal standard correction, the values were 87.8%-118.8% at 1.25 pg / mL and 82.3%-107.1% at 5 ng / mL. It can be seen that the internal standard fully corrected the matrix effect.
[0087] 4) Methodological comparison: Since no method based on liquid chromatography-tandem mass spectrometry detection of copeptin has been found, time-resolved fluorescence immunoassay was used for methodological comparison. The copeptin reagent used was from B·R·A·H·M·S of Thermo Fisher Scientific, patent www.brahms.de / patents , this method has been certified by the European Union. The regression line formula obtained by Passingbablok regression analysis is: y (mass spectrometry) = 0.912x (immunoassay) + 0.897, and the regression coefficient is 0.933 (p < 0.0001). The two methods are consistent.
[0088] According to the specific embodiments provided by the present invention, the present invention discloses the following technical effects:
[0089] The present invention can effectively remove impurities in serum samples by performing immunomagnetic bead enrichment and solid phase extraction on serum, and then use an LC-MS / MS system to directly detect the mass-to-charge ratio of the serum sample, thereby increasing detection specificity and avoiding interference from complex blood components, and has the characteristics of high sensitivity and high specificity.
[0090] In this specification, each embodiment is described in a progressive manner, and each embodiment focuses on the differences from other embodiments. The same or similar parts between the embodiments can be referred to each other. For the method disclosed in the embodiment, since it corresponds to the device disclosed in the embodiment, the description is relatively simple, and the relevant parts can be referred to the device part description.
[0091] The principles and implementation methods of the present invention are described in this article using specific examples. The description of the above embodiments is only used to help understand the method and core idea of the present invention. At the same time, for those skilled in the art, according to the idea of the present invention, there will be changes in the specific implementation methods and application scope. In summary, the content of this specification should not be understood as limiting the present invention.
Claims
1. A method for determining serum copeptin by liquid chromatography-tandem mass spectrometry, characterized in that: include: Step 1: Add serum, internal standard solution, and magnetic beads coated with copeptin antibody to the centrifuge tube in sequence and mix thoroughly; Step 2: Place the centrifuge tube on a magnetic stand to separate the magnetic beads and liquid, and discard the supernatant; Step 3: Wash the magnetic beads with phosphate buffer and remove the buffer mixture; Step 4: Add formic acid aqueous solution to the washed magnetic beads, mix thoroughly, and then add ammonia aqueous solution to form a sample; Step 5: Add trypsin solution to the sample and place it on a shaker for full reaction to form a sample after enzyme digestion; Step 6: performing solid phase extraction on the digested sample to form an extracted sample; Step 7: Use LC-MS / MS system to analyze and detect the extracted sample to obtain a chromatogram of serum copeptin.
2. The method for determining serum copeptin by liquid chromatography-tandem mass spectrometry according to claim 1, characterized in that: The step 6, performing solid phase extraction on the sample after enzyme digestion to form an extracted sample, comprises: Methanol was added to each well of the elution plate, and positive pressure elution was performed using nitrogen gas to activate each well, and pure water was added and positive pressure elution was performed using nitrogen gas again to balance each well; Add ammonia solution to the sample after enzyme digestion, mix well and add to each plate well after activation and equilibrium, use nitrogen gas for positive pressure elution, and the formed target product is enriched in the filler of the plate well; The target product is washed with an aqueous ammonia solution and methanol, respectively, to form a washed target product; The washed target product was eluted with formic acid methanol solution, dried with nitrogen gas, and re-dissolved in acetonitrile aqueous solution to form an extracted sample.
3. The method for determining serum copeptin by liquid chromatography-tandem mass spectrometry according to claim 1, characterized in that: In step 7, an ACQUITY UPLC Peptide BEH C18 Column is used to perform liquid phase separation on the extracted sample, and mobile phase A is 0.03% ammonia solution, mobile phase B is acetonitrile, the liquid phase system performs gradient elution at a flow rate of 0.3 mL / min, and the column oven temperature is set to 40°C.
4. The method for determining serum copeptin by liquid chromatography-tandem mass spectrometry according to claim 1, characterized in that: In the step 1, the copeptin internal standard is diluted with a 0.03% ammonia solution to form an internal standard solution.
5. The method for determining serum copeptin by liquid chromatography-tandem mass spectrometry according to claim 1, characterized in that: In step 4, the volume percentage concentration of the formic acid aqueous solution is 2%, and the volume percentage concentration of the ammonia aqueous solution is 10%. 。
